文献速递临床微生物质量管理与危急值

Etest美罗培南-伐博巴坦多中心药敏试验评估

Multicenter Clinical Evaluation of Etest Meropenem-Vaborbactam (bioMérieux) for Susceptibility Testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa.
PubMed 文献 · J Clin Microbiol · 2019-12-23

多中心评估Etest MEV对629株肠杆菌目和163株铜绿假单胞菌的药敏性能。按CLSI/FDA折点,肠杆菌目总体基本一致率92.4%、分类一致率99.2%、无重大误差;但奇异变形杆菌基本一致率仅34.3%,不可使用。按EUCAST折点,排除奇异变形杆菌后仍出现不可接受的高假敏感率7.1%。

要点

  • Etest MEV在CLSI/FDA折点下对铜绿假单胞菌和肠杆菌目(除奇异变形杆菌)性能良好。
  • 奇异变形杆菌基本一致率仅34.3%,不应使用Etest MEV进行该菌药敏试验。
  • 按EUCAST折点评估时,排除奇异变形杆菌后假敏感率高达7.1%,不可接受。

核心结论

  • 按CLSI/FDA折点,Etest MEV对铜绿假单胞菌和肠杆菌目(除奇异变形杆菌)的药敏试验准确且可重复。
  • 奇异变形杆菌分析性能不可接受,不应使用Etest MEV。
  • 按EUCAST折点评估时,排除奇异变形杆菌后假敏感率7.1%,不可接受。

研究设计与样本

  • 多中心评估Etest MEV与微量肉汤稀释法比较,纳入629株肠杆菌目和163株铜绿假单胞菌分离株。

主要发现

  • 按CLSI/FDA折点,肠杆菌目(含临床和挑战株)Etest MEV基本一致率92.4%、分类一致率99.2%、假敏感率0%、假耐药率0%、次要误差0.8%。
  • 奇异变形杆菌临床和挑战株基本一致率34.3%、分类一致率97.1%、假耐药率0%、次要误差2.9%。
  • 排除奇异变形杆菌后,肠杆菌目Etest MEV基本一致率95.8%、分类一致率99.3%、假敏感率0%、假耐药率0%、次要误差0.7%。
  • 按EUCAST折点,排除奇异变形杆菌的肠杆菌目和铜绿假单胞菌(临床株16株耐药、挑战株12株耐药)假敏感率7.1%、基本一致率95.2%、分类一致率99.2%、假耐药率0.5%。

关键数值与推荐

  • CLSI/FDA折点下,13株肠杆菌目(12株临床和1株挑战)对MEV耐药。
  • CLSI/FDA折点下,除奇异变形杆菌外各菌种基本一致率≥80%。
  • EUCAST折点下,排除奇异变形杆菌的肠杆菌目和铜绿假单胞菌中临床株16株、挑战株12株对MEV耐药。

临床怎么用

  • 使用CLSI/FDA折点报告Etest MEV药敏结果时,对铜绿假单胞菌和肠杆菌目(除奇异变形杆菌)可采纳。
  • 奇异变形杆菌不应使用Etest MEV进行药敏试验。
  • 采用EUCAST折点解读时需注意Etest MEV假敏感率偏高,不宜直接用于临床报告。

局限性

  • 原文未报告多中心的具体中心数量、菌株来源分布及挑战株的详细构成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Meropenem-vaborbactam (MEV) is a novel carbapenem-beta-lactamase inhibitor combination antibiotic approved by the U.S. Food and Drug Administration (FDA) for treatment of complicated urinary tract infections, including pyelonephritis, in adults. In this study, we evaluated the performance of Etest MEV (bioMérieux, Marcy l'Etoile, France) compared to that of broth microdilution for 629 Enterobacterales and 163 Pseudomonas aeruginosa isolates. According to CLSI/FDA breakpoints, 13 Enterobacterales isolates (12 clinical and 1 challenge) were resistant to MEV. Overall, Etest MEV demonstrated 92.4% essential agreement (EA), 99.2% category agreement (CA), 0% very major errors (VME), 0% major errors (ME), and 0.8% minor errors (mE) with clinical and challenge isolates of Enterobacterales Individual species demonstrated EA rates of ≥80%, with the exception of Proteus mirabilis, for which clinical and challenge isolates demonstrated 34.3% EA, 97.1% CA, 0% ME, and 2.9% mE, precluding the use of Etest MEV with this species. Excluding P. mirabilis, MEV Etest MEV demonstrated 95.8% EA, 99.3% CA, 0% VME, 0% ME, and 0.7% mE with Enterobacterales isolates. When evaluated using European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints, Etest MEV performance with clinical (16 MEV resistant) and challenge (12 MEV resistant) isolates of Enterobacterales (excluding P. mirabilis) and P. aeruginosa demonstrated an unacceptably high VME rate of 7.1% despite 95.2% EA, 99.2% CA, and 0.5% ME compared to the reference method. In conclusion, we report that Etest MEV is accurate and reproducible for MEV susceptibility testing for P. aeruginosa and Enterobacterales, with the exception of P. mirabilis, using CLSI/FDA breakpoints. Etest MEV should not be used with P. mirabilis due to unacceptable analytical performance.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Jean S, Garrett S, Anglade C, et al. Multicenter Clinical Evaluation of Etest Meropenem-Vaborbactam (bioMérieux) for Susceptibility Testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa. J Clin Microbiol. 2019. PMID: 31619532. doi:10.1128/JCM.01205-19

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。